Article Information
History
- August 1, 2019.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- aStudies of Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, McGill University, 3647 Peel Street, Montreal QC H3A 1X1
- ↵*Corresponding author, Email: jonathan.kimmelman{at}mcgill.ca, Telephone: 514-398-6980, Fax: 514-398-8349
Posted August 01, 2019.
Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio
